Skip to content
2000
Volume 33, Issue 7
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

The high incidence of Non-Alcoholic Fatty Liver Disease (NAFLD) as a hepatic component of metabolic syndrome is attributed to the ongoing rise in obesity rates. Given the beneficial effects of hydroxychloroquine (HCQ) on metabolism, there is growing interest in combining it with fisetin (FSN), a natural product, to treat NAFLD more effectively.

Objective

The efficacy and safety of the combined therapy of FSN and HCQ in animal models of NAFLD were assessed, focusing on liver function, insulin sensitivity, oxidative stress, and inflammation.

Materials and Methods

C57BL/6J mice were fed either a standard chow diet or a high-fat diet to induce NAFLD. FSN and HCQ were administered to the mice, and biochemical parameters related to glucose and lipid metabolism, as well as oxidative stress markers, were measured in serum and liver tissue. Analyses included Oil Red O staining, mRNA levels of key lipid metabolism molecules, and immunohistochemical assessments of macrophage infiltration. Statistical analyses were performed using GraphPad Prism 9.

Results

While the HCQ group exhibited some improvements in certain markers, it also displayed adverse effects. The FSN group, particularly the FSN + HCQ group, effectively reversed insulin sensitivity, glucose homeostasis, and NAFLD markers by modulating lipid metabolism and inflammation pathways. HCQ exacerbated oxidative stress, which was mitigated by the effects of FSN.

Conclusion

Despite concerns regarding the long-term side effects of HCQ, its combination with FSN presents a promising approach for improving the management of NAFLD by reducing risks and enhancing outcomes.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673342421241126060049
2025-02-11
2026-03-02

  • From This Site

    /content/journals/cmc/10.2174/0109298673342421241126060049
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. YounossiZ.M. KoenigA.B. AbdelatifD. FazelY. HenryL. WymerM. Global epidemiology of nonalcoholic fatty liver disease-eta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016641738410.1002/hep.2843126707365
     [Google Scholar]
  2. YounossiZ.M. GolabiP. de AvilaL. PaikJ.M. SrishordM. FukuiN. QiuY. BurnsL. AfendyA. NaderF. The global epidemiology of NAFLD and NASH in patients with Type 2 diabetes: A systematic review and meta-analysis.J. Hepatol.201971479380110.1016/j.jhep.2019.06.02131279902
     [Google Scholar]
  3. NassirF. NAFLD: Mechanisms, Treatments, and Biomarkers.Biomolecules202212682410.3390/biom1206082435740949
     [Google Scholar]
  4. DonnellyK.L. SmithC.I. SchwarzenbergS.J. JessurunJ. BoldtM.D. ParksE.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.J. Clin. Invest.200511551343135110.1172/JCI2362115864352
     [Google Scholar]
  5. Alves-BezerraM. CohenD.E. Triglyceride metabolism in the liver.Compr. Physiol.2017811829357123
     [Google Scholar]
  6. ClareK. DillonJ.F. BrennanP.N. Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD.J. Clin. Transl. Hepatol.202210593994610.14218/JCTH.2022.0006736304513
     [Google Scholar]
  7. AhmedB. SultanaR. GreeneM.W. Adipose tissue and insulin resistance in obese.Biomed. Pharmacother.202113711131510.1016/j.biopha.2021.11131533561645
     [Google Scholar]
  8. HageM.P. Al-BadriM.R. AzarS.T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.Ther. Adv. Endocrinol. Metab.201454778510.1177/204201881454720425343023
     [Google Scholar]
  9. Hydroxychloroquine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.Bethesda, MDNational Institute of Diabetes and Digestive and Kidney Diseases2012
     [Google Scholar]
  10. InfanteM. RicordiC. FabbriA. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.J. Diabetes202012965966710.1111/1753‑0407.1305332401405
     [Google Scholar]
  11. StoianA.P. CatrinoiuD. RizzoM. CerielloA. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story.Diabetes Metab. Res. Rev.2021372e337910.1002/dmrr.337932592507
     [Google Scholar]
  12. DuttaD. JindalR. MehtaD. KumarM. SharmaM. Efficacy and safety of hydroxychloroquine for managing glycemia in Type-2 diabetes: A systematic review and meta-analysis.J. Postgrad. Med.2022682859210.4103/jpgm.JPGM_301_2135466661
     [Google Scholar]
  13. WangL. YanY. WuL. PengJ. Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development.Pharmacol. Res.202319610692510.1016/j.phrs.2023.10692537714392
     [Google Scholar]
  14. PalH.C. PearlmanR.L. AfaqF. Fisetin and its role in chronic diseases.Adv. Exp. Med. Biol.201692821324410.1007/978‑3‑319‑41334‑1_1027671819
     [Google Scholar]
  15. GrynkiewiczG. DemchukO.M. New perspectives for fisetin.Front Chem.2019769710.3389/fchem.2019.0069731750288
     [Google Scholar]
  16. MaherP. DarguschR. EhrenJ.L. OkadaS. SharmaK. SchubertD. Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes.PLoS One201166e2122610.1371/journal.pone.002122621738623
     [Google Scholar]
  17. AL-IshaqR.K. AbotalebM. KubatkaP. KajoK. BüsselbergD. Flavonoids and their anti-diabetic effects: Cellular mechanisms and effects to improve blood sugar levels.Biomolecules20199943010.3390/biom909043031480505
     [Google Scholar]
  18. PrasathG.S. PillaiS.I. SubramanianS.P. Fisetin improves glucose homeostasis through the inhibition of gluconeogenic enzymes in hepatic tissues of streptozotocin induced diabetic rats.Eur. J. Pharmacol.201474024825410.1016/j.ejphar.2014.06.06525064342
     [Google Scholar]
  19. PouwelsS. SakranN. GrahamY. LealA. PintarT. YangW. KassirR. SinghalR. MahawarK. RamnarainD. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss.BMC Endocr. Disord.20222216310.1186/s12902‑022‑00980‑135287643
     [Google Scholar]
  20. NgC.H. HuangD.Q. NguyenM.H. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.Clin. Mol. Hepatol.202228479080110.3350/cmh.2022.007035545437
     [Google Scholar]
  21. MengC.C. ChenD.Y. ChenY.H. HuangW.N. ChenH.H. Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: A nationwide, population-based cohort study.Int. J. Rheum. Dis.2024271e1500310.1111/1756‑185X.1500338073585
     [Google Scholar]
  22. ACR. Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients.2023Available From: https://rheumatology.org/press-releases/study-finds-hcq-lowers-risk-of-nonalcoholic-fatty-liver-disease-in-ra-patients
  23. HasanM.A. AmmarO.A. AmerM.A. OthmanA.I. ZigheberF. El-MissiryM.A. Hydroxychloroquine improves high-fat-diet-induced obesity and organ dysfunction via modulation of lipid level, oxidative stress, and inflammation.Egyptian J. Basic Appl. Sci.202310136837910.1080/2314808X.2023.2211832
     [Google Scholar]
  24. CarvalhoA.A.S. Side effects of chloroquine and hydroxychloroquine on skeletal muscle: A narrative review.Curr. Pharmacol. Rep.20206636437210.1007/s40495‑020‑00243‑433163329
     [Google Scholar]
  25. GressierF. VerstuyftC. BecquemontL. FalissardB. CorrubleE. Psychiatric side effects of chloroquine.J. Clin. Psychiatry202081520l1347610.4088/JCP.20l1347632726000
     [Google Scholar]
  26. FernerR.E. AronsonJ.K. Chloroquine and hydroxychloroquine in COVID-19.BMJ2020369m143210.1136/bmj.m143232269046
     [Google Scholar]
  27. BlignautM. EspachY. van VuurenM. DhanabalanK. HuisamenB. Revisiting the cardiotoxic effect of chloroquine.Cardiovasc. Drugs Ther.201933111110.1007/s10557‑018‑06847‑930635818
     [Google Scholar]
  28. WaskoM.C.M. McClureC.K. KelseyS.F. HuberK. OrchardT. ToledoF.G.S. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: A randomised trial.Diabetologia201558102336234310.1007/s00125‑015‑3689‑226197707
     [Google Scholar]
  29. NaddafE. PaulP. AbouEzzeddineO.F. Chloroquine and hydroxychloroquine myopathy: clinical spectrum and treatment outcomes.Front. Neurol.20211161607510.3389/fneur.2020.61607533603707
     [Google Scholar]
  30. FanZ. XiaoQ. Impaired autophagic flux contributes to muscle atrophy in obesity by affecting muscle degradation and regeneration.Biochem. Biophys. Res. Commun.2020525246246810.1016/j.bbrc.2020.02.11032102751
     [Google Scholar]
  31. NavarroC.D.C. FigueiraT.R. FranciscoA. Dal’BóG.A. RonchiJ.A. RovaniJ.C. EscanhoelaC.A.F. OliveiraH.C.F. CastilhoR.F. VercesiA.E. Redox imbalance due to the loss of mitochondrial NAD(P)-transhydrogenase markedly aggravates high fat diet-induced fatty liver disease in mice.Free Radic. Biol. Med.201711319020210.1016/j.freeradbiomed.2017.09.02628964917
     [Google Scholar]
  32. ChenZ. TianR. SheZ. CaiJ. LiH. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease.Free Radic. Biol. Med.202015211614110.1016/j.freeradbiomed.2020.02.02532156524
     [Google Scholar]
  33. JinE.S. LeeM.H. MurphyR.E. MalloyC.R. Pentose phosphate pathway activity parallels lipogenesis but not antioxidant processes in rat liver.Am. J. Physiol. Endocrinol. Metab.20183146E543E55110.1152/ajpendo.00342.201729351478
     [Google Scholar]
  34. KiffinR. ChristianC. KnechtE. CuervoA.M. Activation of chaperone-mediated autophagy during oxidative stress.Mol. Biol. Cell200415114829484010.1091/mbc.e04‑06‑047715331765
     [Google Scholar]
  35. QuX. ShengJ. ShenL. SuJ. XuY. XieQ. WuY. ZhangX. SunL. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS.PLoS One2017123e017371210.1371/journal.pone.017371228301876
     [Google Scholar]
  36. CircuM. CardelliJ. BarrM. O’ByrneK. MillsG. El-OstaH. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small- cell lung cancer cells.PLoS One2017129e018492210.1371/journal.pone.018492228945807
     [Google Scholar]
  37. TrivediP.C. BartlettJ.J. PulinilkunnilT. Lysosomal biology and function: Modern view of cellular debris bin.Cells202095113110.3390/cells905113132375321
     [Google Scholar]
  38. Navarro-YepesJ. BurnsM. AnandhanA. KhalimonchukO. del RazoL.M. Quintanilla-VegaB. PappaA. PanayiotidisM.I. FrancoR. Oxidative stress, redox signaling, and autophagy: Cell death versus survival.Antioxid. Redox Signal.2014211668510.1089/ars.2014.583724483238
     [Google Scholar]
  39. DaiX. KuangQ. SunY. XuM. ZhuL. GeC. TanJ. WangB. Fisetin represses oxidative stress and mitochondrial dysfunction in NAFLD through suppressing GRP78-mediated endoplasmic reticulum (ER) stress.J. Funct. Foods20229010495410.1016/j.jff.2022.104954
     [Google Scholar]
  40. ShiY.S. LiC.B. LiX.Y. WuJ. LiY. FuX. ZhangY. HuW.Z. Fisetin attenuates metabolic dysfunction in mice challenged with a high-fructose diet.J. Agric. Food Chem.201866318291829810.1021/acs.jafc.8b0214030040414
     [Google Scholar]
  41. SandireddyR. YerraV.G. KomirishettiP. AretiA. KumarA. Fisetin imparts neuroprotection in experimental diabetic neuropathy by modulating Nrf2 and NF-κB pathways.Cell. Mol. Neurobiol.201636688389210.1007/s10571‑015‑0272‑926399251
     [Google Scholar]
  42. NaeimiA.F. AlizadehM. Antioxidant properties of the flavonoid fisetin: An updated review of in vivo and in vitro studies.Trends Food Sci. Technol.201770344410.1016/j.tifs.2017.10.003
     [Google Scholar]
  43. SchrezenmeierE. DörnerT. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology.Nat. Rev. Rheumatol.202016315516610.1038/s41584‑020‑0372‑x32034323
     [Google Scholar]
  44. AlisiA. CarpinoG. OliveiraF.L. PaneraN. NobiliV. GaudioE. The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications.Mediators Inflamm.2017201711510.1155/2017/816242128115795
     [Google Scholar]
  45. ZhangW. LangR. Macrophage metabolism in nonalcoholic fatty liver disease.Front. Immunol.202314125759610.3389/fimmu.2023.125759637868954
     [Google Scholar]
  46. RichardS.A. KampoS. HechavarriaM.E. SackeyM. BuunaaimA.D.B. KuugbeeE.D. AnabahT.W. Elucidating the pivotal immunomodulatory and anti-inflammatory potentials of chloroquine and hydroxychloroquine.J. Immunol. Res.2020202011310.1155/2020/458261233062720
     [Google Scholar]
  47. DaiC. XiaoX. LiD. TunS. WangY. VelkovT. TangS. Chloroquine ameliorates carbon tetrachloride-induced acute liver injury in mice via the concomitant inhibition of inflammation and induction of apoptosis.Cell Death Dis.2018912116410.1038/s41419‑018‑1136‑230478280
     [Google Scholar]
  48. ChoiM.S. ChoiJ.Y. KwonE.Y. Fisetin alleviates hepatic and adipocyte fibrosis and insulin resistance in diet-induced obese mice.J. Med. Food202023101019103210.1089/jmf.2019.461932856978
     [Google Scholar]
  49. XuM. GeC. QinY. GuT. LvJ. WangS. MaY. LouD. LiQ. HuL. NieX. WangM. HuangP. TanJ. Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: Inhibition by dietary fisetin intervention.Food Funct.20191031302131610.1039/C8FO01615A30793717
     [Google Scholar]
  50. BrankovićM. JovanovićI. DukićM. RadonjićT. OprićS. KlašnjaS. ZdravkovićM. Lipotoxicity as the leading cause of non-alcoholic steatohepatitis.Int. J. Mol. Sci.2022239514610.3390/ijms2309514635563534
     [Google Scholar]
  51. KubotaN. KubotaT. KajiwaraE. IwamuraT. KumagaiH. WatanabeT. InoueM. TakamotoI. SasakoT. KumagaiK. KohjimaM. NakamutaM. MoroiM. SugiK. NodaT. TerauchiY. UekiK. KadowakiT. Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity.Nat. Commun.2016711297710.1038/ncomms1297727708333
     [Google Scholar]
  52. CunninghamR.P. Porat-ShliomN. Liver zonation – revisiting old questions with new technologies.Front. Physiol.20211273292910.3389/fphys.2021.73292934566696
     [Google Scholar]
  53. SaltielA.R. Insulin signaling in health and disease.J. Clin. Invest.20211311e14224110.1172/JCI14224133393497
     [Google Scholar]
  54. SunnyN.E. ParksE.J. BrowningJ.D. BurgessS.C. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease.Cell Metab.201114680481010.1016/j.cmet.2011.11.00422152305
     [Google Scholar]
  55. SunnyN.E. BrilF. CusiK. Mitochondrial adaptation in nonalcoholic fatty liver disease: Novel mechanisms and treatment strategies.Trends Endocrinol. Metab.201728425026010.1016/j.tem.2016.11.00627986466
     [Google Scholar]
  56. FujitaK. NozakiY. WadaK. YonedaM. FujimotoY. FujitakeM. EndoH. TakahashiH. InamoriM. KobayashiN. KirikoshiH. KubotaK. SaitoS. NakajimaA. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis.Hepatology200950377278010.1002/hep.2309419650159
     [Google Scholar]
  57. ServiddioG. GiudettiA.M. BellantiF. PrioreP. RolloT. TamborraR. SiculellaL. VendemialeG. AltomareE. GnoniG.V. Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet.PLoS One201169e2408410.1371/journal.pone.002408421909411
     [Google Scholar]
  58. GoodarziG. TehraniS.S. PanahiG. BahramzadehA. MeshkaniR. Combination therapy of metformin and p- coumaric acid mitigates metabolic dysfunction associated with obesity and nonalcoholic fatty liver disease in high- fat diet obese C57BL/6 mice.J. Nutr. Biochem.202311810936910.1016/j.jnutbio.2023.10936937100305
     [Google Scholar]
  59. LindenA.G. LiS. ChoiH.Y. FangF. FukasawaM. UyedaK. HammerR.E. HortonJ.D. EngelkingL.J. LiangG. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice.J. Lipid Res.201859347548710.1194/jlr.M08183629335275
     [Google Scholar]
  60. HanH.S. KangG. KimJ.S. ChoiB.H. KooS.H. Regulation of glucose metabolism from a liver-centric perspective.Exp. Mol. Med.2016483e218e21810.1038/emm.2015.12226964834
     [Google Scholar]
  61. LiouC. J. WeiC. H. ChenY. L. ChengC. Y. WangC. L. HuangW. C. Fisetin protects against hepatic steatosis through regulation of the sirt1/AMPK and fatty acid β-oxidation signaling pathway in high-fat diet-induced obese mice.Cell Physiol. Biochem.201849118701884
     [Google Scholar]
  62. ChoY. ChungJ.H. DoH.J. JeonH.J. JinT. ShinM.J. Effects of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague–dawley rats fed on a high fat diet.Food Chem.20131391-472072710.1016/j.foodchem.2013.01.06023561166
     [Google Scholar]
  63. PrasathG.S. SubramanianS.P. Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats.Eur. J. Pharmacol.2011668349249610.1016/j.ejphar.2011.07.02121816145
     [Google Scholar]
  64. QiaoX. ZhouZ.C. NiuR. SuY.T. SunY. LiuH.L. TengJ.L. YeJ.N. ShiH. YangC.D. ChengX.B. Hydroxychloroquine improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism.Front. Pharmacol.20191085510.3389/fphar.2019.0085531427967
     [Google Scholar]
  65. AshmawyA.I. El-AbharH.S. AbdallahD.M. AliM.A. Chloroquine modulates the sulforaphane anti-obesity mechanisms in a high-fat diet model: Role of JAK-2/STAT-3/SOCS-3 pathway.Eur. J. Pharmacol.202292717506610.1016/j.ejphar.2022.17506635643302
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673342421241126060049
Loading
Improving Non-alcoholic Fatty Liver Disease Treatment in High-fat Diet Fed Mice with Fisetin and Hydroxychloroquine: The Cooperative Pathways for Improved Metabolic Health
Curr. Med. Chem. 33, 1467 (2026); https://doi.org/10.2174/0109298673342421241126060049
/content/journals/cmc/10.2174/0109298673342421241126060049
/content/journals/cmc/10.2174/0109298673342421241126060049
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): fisetin; hydroxychloroquine; inflammation; metabolic syndrome; NAFLD; oxidative stress

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test